News

Nanomerics is pleased to announce the imminent publication of key patents underpinning its NM127 asset. Nanomerics has been notified by the US Patent and Trademark Office of the imminent publication of US10213474 on the 26th of February.  This key patent further strengthens Nanomerics patent portfolio and enables Nanomerics to continue the development of NM127.  Nanomerics is also pleased to announce a notice of allowance issued by the Japanese Intellectual Property Office for application JP2016-526933.

Today Nanomerics announced the award of a research grant from Innovate UK.  The award has been made to progress the development of NM127, Nanomerics’ pain asset.  The award will fund a collaboration between Nanomerics Ltd.  and Alchemy Pharmatech Ltd. and will involve the coupling of Alchemy Pharmatech’s Naltos nasal delivery device with Nanomerics’ enkephalin based formulation for the treatment of breakthrough, neuropathic and post operative pain.

Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant.   This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets.  Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution.  This is a major component of its business strategy.

 Nanomerics to attend Biopharm America (5th - 6th September 2018) in Boston

Nanomerics has entered into an Engineering and Physical Sciences Research Council (EPSRC) funded academic collaboration with scientists from Exeter University, Cambridge University, University College London and The Science and Technology Facilities Council’s Central Laser Facility.   The £5.7 million pound grant will generate new data on the diagnosis and treatment of solid tumours with gold nanoparticles.